Peppers J, et al. - Experts evaluated the safety and effectiveness of tapinarof cream (2 concentrations; 2 application frequencies) in patients with atopic dermatitis (AD). Investigator Global Assessment (IGA) score of clear or almost clear (0 or 1), and minimum 2-grade improvement (“treatment success”) at Week 12 was the primary endpoint. Findings suggested the efficacy and good tolerability of tapinarof cream in adolescent and adult patients with AD. For 4 weeks after end of tapinarof treatment, the treatment success was maintained.